Efficacy of Voluven® for the Prevention of Hypotension During Spinal Anesthesia for Cesarean Section

Verified by: Fresenius Kabi, March 2011
First Received: June 6, 2008 | Last Updated: March 8, 2011 | Phase: Phase 4 | Start Date: June 2008
Overall Status: Completed | Estimated Enrollment: 169
  • …
  • Tell a FriendPrint

The aim of the study is to evaluate the efficacy of Voluven® in the prevention of maternal hypotension in women undergoing spinal anesthesia for cesarean...

Brief Summary

Official Title: “Evaluation of the Efficacy of 6% Hydroxyethyl Starch (HES, 130/0.4) in Normal Saline Compared to Ringer's Lactate Solution for the Prevention of Hypotension During Spinal Anesthesia for Cesarean Section”

The aim of the study is to evaluate the efficacy of Voluven® in the prevention of maternal hypotension in women undergoing spinal anesthesia for cesarean section

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
  • Study Primary Completion Date: December 2009

Detailed Clinical Trial Description

Intravenous fluid administration prior to spinal anesthesia for cesarean section is an established part of anesthetic practice for the prevention of maternal hypotension.

Systematic reviews of clinical data suggest the usefulness of administering colloids to decrease the incidence of hypotension This study will compare the clinical efficacy and safety of HES 130/0.4 (6%) in normal saline vs. Ringer's lactate solution in prevention of hypotension during spinal anesthesia for elective cesarean section.

Intervention(s) in this Clinical Trial

  • Drug: HES 130/0.4 (6%) in sodium chloride (solution for infusion)
    • 500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
  • Drug: Ringer's Lactate solution
    • 1000 mL Ringer's Lactate solution

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: Group A
    • 500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
  • Active Comparator: Group B
    • 1000 mL Ringer's Lactate solution

Outcome Measures for this Clinical Trial

Primary Measures

  • Incidence of hypotension
    • Time Frame: Time between induction of spinal anesthesia until delivery
      Safety Issue?: No

Secondary Measures

  • Minimum of systolic blood pressure until delivery
    • Time Frame: between induction of anesthesia and delivery
      Safety Issue?: No
  • Maternal heart rate between induction of anesthesia and delivery
    • Time Frame: between induction of anesthesia and delivery
      Safety Issue?: No
  • Onset and duration of hypotension between induction of anesthesia and delivery
    • Time Frame: between induction of anesthesia and delivery
      Safety Issue?: No
  • Phenylephrine requirements to keep systolic blood pressure equal or higher than 95% of baseline value
    • Time Frame: between induction of anesthesia and delivery
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • elective cesarean section applying spinal anesthesia
  • ≥ week 37 of gestation
  • Singleton pregnancy

Exclusion Criteria:

  • Suspicion of any hypertensive disease
  • Parturient in labor

Gender Eligibility for this Clinical Trial: Female

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Investigator Information

Lead Investigator: Fresenius Kabi Industry

Overall Clinical Trial Officials and Contacts

Frederic Mercier, Professor Principal Investigator Hôpital Béclère, Service Anesthésie-Réanimation, 157 Rue de la Porte de Trivaux, 92140 Clamart, France  

Additional Information

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00694343

Study ID Number: 07-HE06-03

ClinicalTrials.gov Identifier: NCT00694343

Health Authority: France: Afssaps - French Health Products Safety Agency

  • …
  • Tell a FriendPrint

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00694343